Congestive heart failure.
A review of the epidemiology, pathophysiology, and treatment of congestive heart failure is presented, with particular attention given to newer modalities of therapy.
D000631:Aminopyridines / Q000627:therapeutic use; D000676:Amrinone; D000806:Angiotensin-Converting Enzyme Inhibitors; D002301:Cardiac Glycosides / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004280:Dobutamine / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D020105:Milrinone; D009566:Nitrates / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D011224:Prazosin / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D013566:Sympathomimetics / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000631:Aminopyridines; D000806:Angiotensin-Converting Enzyme Inhibitors; D002301:Cardiac Glycosides; D002316:Cardiotonic Agents; D004232:Diuretics; D009566:Nitrates; D011728:Pyridones; D013566:Sympathomimetics; D014665:Vasodilator Agents; D009599:Nitroprusside; D006830:Hydralazine; D004280:Dobutamine; D020105:Milrinone; D000676:Amrinone; D004298:Dopamine; D011224:Prazosin